Generic Medicine Info
Indications and Dosage
Hypersensitivity reactions, Pruritic skin disorders
Adult: As 2% cream: Apply sparingly onto affected area(s) 2-3 times daily for up to 3 days.
Child: ≥2 yr Same as adult dose.
Application to eczematous skin conditions or extensively broken skin surfaces.
Special Precautions
Childn. Pregnancy and lactation.
Adverse Reactions
Significant: Rarely, skin sensitisation.
Immunologic: Local hypersensitivity reactions.
Patient Counseling Information
Avoid contact on large areas of skin, broken, sunburnt, cut or grazed skin. This drug may cause somnolence and mild disorientation, if affected, do not drive or operate machinery.
Mechanism of Action: Mepyramine is an ethylenediamine derived antihistamine w/ anti-pruritic and local analgesic action. It competitively blocks histamine at H1 receptor sites thus inhibiting the effect of histamine in the body.
Absorption: Readily absorbed through the skin.
Metabolism: Metabolised in the liver.
Excretion: Mainly via urine as metabolites.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Pyrilamine, CID=4992, (accessed on Jan. 22, 2020)

Store below 25°C.
MIMS Class
Antihistamines & Antiallergics / Topical Antihistamines/Antipruritics
ATC Classification
D04AA02 - mepyramine ; Belongs to the class of topical antihistamines used in the treatment of pruritus.
Bite and Sting Relief Antihistamine Cream Boots Bite & Sting Relief 2 Years Plus Antihistamine Cream (The Boots Company PLC). MHRA. Accessed 19/07/17.

Buckingham R (ed). Mepyramine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 19/07/17.

Sanofi-Aventis New Zealand Limited. Anthisan Cream data sheet 5 May 2014. Medsafe. Accessed 19/07/17.

Disclaimer: This information is independently developed by MIMS based on Mepyramine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in